No Data
No Data
Viva Biotech Announces Share Option Schemes
Via Biotech (01873): Via Shanghai has decided to adopt the first phase of the Via Shanghai equity incentive plan and the second phase of the Via Shanghai equity incentive plan
VIA Biotech (01873) issued an announcement. On May 31, 2024, VIA Shanghai shareholders have decided to adopt VIA...
Changes in Hong Kong stocks | CRO concept stocks picked up in early trading, and many companies began to adjust their business in the US. Institutions say industry demand is expected to recover in the second half of the year
CRO concept stocks picked up in early trading. As of press release, Viva Biotech (01873) rose 3.13% to HK$0.66; Kanglong Chemical (03759) rose 2.82% to HK$9.86; Pharmaceutical Biotech (02269) rose 2.68% to HK$11.5; and Pharmaceuticals (02359) rose 2.31% to HK$35.45.
Changes in Hong Kong stocks | CRO concept stocks continue to rebound, the downstream demand side needs to improve, and domestic CXO companies still have a competitive advantage
CRO concept stocks continued to rebound. As of press release, Viva Biotech (01873) rose 8.93% to HK$0.61; Kingsley Biotech (01548) rose 8.35% to HK$11.94; Kanglong Chemical (03759) rose 5.91% to HK$10.04; and Pharmaceutical Biotech (02269) rose 5.79% to HK$14.26.
維亞生物:2023年度報告
The biomedical sector gained strength in the afternoon, and Pharmaceutical Federation (02268) rose 8.59%. Institutions say the industry still has structural growth this year
Jinwu Financial News | The biomedical sector gained strength in the afternoon, with Pharmaceuticals (02268) up 8.59%, Rongchang Biotech (09995) up 6.53%, Cinda Biotech (01801) up 6.48%, Cansino Biotech (06185) 6.4%, Viva Biotech (01873) 5.88%, Hehuang Pharmaceutical (00013) up 5.58%, and Kang Fang Biotech (09926) up 5.41%. Huaxin Securities said that the growth of the industry in the first quarter of 2024 was clearly affected by the base for the same period, such as retail pharmacies, POCT, etc., and the outlook is for the whole of 2024.
No Data